Outcome-based reimbursement : the solution to high drug spending?
Year of publication: |
2022
|
---|---|
Authors: | Xu, Liang ; Li, Hongmin ; Zhao, Hui |
Published in: |
Manufacturing & service operations management : M & SOM. - Linthicum, Md. : Informs, ISSN 1526-5498, ZDB-ID 2023273-1. - Vol. 24.2022, 4, p. 2029-2047
|
Subject: | drug pricing | formulary design | multinomial logit models | outcome-based reimbursement | risk aversion | risk sharing | Arzneimittel | Pharmaceuticals | Risikoaversion | Risk aversion | Logit-Modell | Logit model | Gesundheitskosten | Health care costs |
-
Nakamura, Hiroshi, (2019)
-
Outcome-based pricing for new pharmaceuticals via rebates
Adida, Elodie, (2021)
-
Conditional approval and value-based pricing for new health technologies
Yapar, Ozge, (2024)
- More ...
-
"Not a box of nuts and bolts" : distribution channels for specialty drugs
Xu, Liang, (2023)
-
Inducing Compliance with Post-Market Studies for Drugs Under FDA’s Accelerated Approval Pathway
Xu, Liang, (2019)
-
Inducing compliance with postmarket studies for drugs under FDA's accelerated approval pathway
Xu, Liang, (2021)
- More ...